The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...
Depression risk lower with GLP-1 receptor agonists versus DPP-4 inhibitors in seniors, study reveals
is associated with a modestly lower risk for depression compared with dipeptidyl peptidase-4 inhibitor (DPP-4i) use, according to a study published online Feb. 25 in the Annals of Internal Medicine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback